Osaic Holdings
ABUS icon

Osaic Holdings’s Arbutus Biopharma ABUS Stock Holding History

Osaic Holdings’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.47M Sell
1,347,866
-261
-0% -$1.15K 0.01% 1335
2026
Q1 		$6.07M Sell
1,348,127
-97
-0% -$424 0.01% 1223
2025
Q4 		$6.48M Buy
1,348,224
+9,721
+0.7% +$43.7K 0.01% 1201
2025
Q3 		$5.97M Sell
1,338,503
-13
-0% -$48 0.01% 1336
2025
Q2 		$4.14M Sell
1,338,516
-6,390
-0.5% -$21.2K 0.01% 1371
2025
Q1 		$4.69M Sell
1,344,906
-2,418
-0.2% -$8.06K 0.01% 1074
2024
Q4 		$4.41M Sell
1,347,324
-25,030
-2% -$92.1K 0.01% 1108
2024
Q3 		$5.28M Buy
1,372,354
+2,515
+0.2% +$9.65K 0.01% 1005
2024
Q2 		$4.23M Buy
1,369,839
+2,300
+0.2% +$6.9K 0.01% 1106
2024
Q1 		$3.53M Hold
1,367,539
– – 0.01% 1288
2023
Q4 		$3.42M Sell
1,367,539
-500
-0% -$979 0.01% 1462
2023
Q3 		$2.78M Buy
1,368,039
+1,000
+0.1% +$2.1K ﹤0.01% 1715
2023
Q2 		$3.14M Sell
1,367,039
-9,484
-0.7% -$24.7K 0.01% 1505
2023
Q1 		$4.17M Hold
1,376,523
– – 0.01% 1285
2022
Q4 		$3.21M Buy
1,376,523
+12,000
+0.9% +$28.7K 0.01% 1399
2022
Q3 		$2.61M Hold
1,364,523
– – 0.01% 1433
2022
Q2 		$3.7M Sell
1,364,523
-1
-0% -$3 0.01% 1240
2022
Q1 		$4.07M Sell
1,364,524
-370
-0% -$1.13K 0.01% 1355
2021
Q4 		$5.31M Buy
1,364,894
+330
+0% +$1.28K 0.01% 1063
2021
Q3 		$5.85M Sell
1,364,564
-5,125
-0.4% -$17.1K 0.01% 963
2021
Q2 		$4.15M Sell
1,369,689
-400
-0% -$1.24K 0.01% 1152
2021
Q1 		$4.56M Sell
1,370,089
-1,000
-0.1% -$3.86K 0.01% 1016
2020
Q4 		$4.87M Buy
1,371,089
+10,800
+0.8% +$37.8K 0.01% 895
2020
Q3 		$4.26M Sell
1,360,289
-414,646
-23% -$1.26M 0.01% 854
2020
Q2 		$3.23M Buy
1,774,935
+20
+0% +$33 0.01% 944
2020
Q1 		$1.79M Buy
+1,774,915
New +$4.8M 0.01% 1128

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Osaic Holdings's ABUS Position: Q2 2026 in Review

Osaic Holdings reduced its Arbutus Biopharma (ABUS) stake by 0.02% in Q2 2026, selling an estimated $1.15K and leaving 1,347,866 shares worth $6.47M. The position accounts for 0.01% of the portfolio, ranked #1335.

Osaic Holdings first reported a position in ABUS in Q1 2020 and has held it in 26 quarters since. The position peaked at $6.48M in Q4 2025. 177 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • Osaic Holdings held 1,347,866 shares of Arbutus Biopharma worth $6.47M as of Q2 2026.
  • Osaic Holdings sold 261 Arbutus Biopharma shares in Q2 2026, an estimated $1.15K.
  • Arbutus Biopharma made up 0.01% of Osaic Holdings's portfolio in Q2 2026, its #1335 holding.
  • Osaic Holdings first reported a position in Arbutus Biopharma in Q1 2020 and has held it in 26 quarters since.
  • Osaic Holdings's Arbutus Biopharma position peaked at $6.48M in Q4 2025.
  • 177 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Osaic Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.